Home Applications 207145 Application 207145
Type NDA
Sponsor US WORLDMEDS LLC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 XADAGO SAFINAMIDE MESYLATE TABLET;ORAL 50MG Yes No 002 XADAGO SAFINAMIDE MESYLATE TABLET;ORAL 100MG Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N207145-001 XADAGO SAFINAMIDE MESYLATE EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 N207145-002 XADAGO SAFINAMIDE MESYLATE EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 2 matching rows.
Orange Book patents# Current patent rows page 1 of 1 · 6 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 N207145-002 8283380 2031-03-21 U-1993 2017-04-20
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 3 · 88 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-10-15 13:18:30 2026-09 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 c2088c7a36db…2026-09-14 22:38:34 2026-08 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 84e616aacf4f…2026-08-18 06:07:40 2026-07 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL AB RLD 2017-03-21 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL AB RLD, RS 2017-03-21 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N207145-001 XADAGO EQ 50MG BASE TABLET / ORAL RLD 2017-03-21 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 N207145-002 XADAGO EQ 100MG BASE TABLET / ORAL RLD, RS 2017-03-21 4b0b4de00fa7…
Observed Orange Book normalized TE history# Observed Orange Book patent history# Patent history page 1 of 7 · 264 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 c2088c7a36db…2026-09-14 22:38:34 2026-08 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 84e616aacf4f…2026-08-18 06:07:40 2026-07 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-002 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N207145-002 8283380 2031-03-21 U-1993 2017-04-20 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-001 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-001 8076515 2028-12-10 U-1993 Drug substance, Drug product 2017-04-20 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-001 8283380 2031-03-21 U-1993 2017-04-20 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N207145-002 8278485 2027-06-08 U-1993 Drug substance 2017-04-20 fd3edfee7708…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 18 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 27505-110 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-110 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations, LLC NDA Current 27505-110 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations, LLC NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-110 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-110 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-111 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-111 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations, LLC NDA Current 27505-111 Xadago safinamide mesylate US WorldMeds, LLC NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations, LLC NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-111 Xadago safinamide mesylate MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. NDA Current 27505-111 Xadago safinamide mesylate US WorldMeds, LLC NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 68325 SUPPL 2021-08-10 68316 SUPPL 2021-08-09 61100 SUPPL 2019-11-29 61081 SUPPL 2019-11-27 48775 SUPPL 2017-06-20 48756 SUPPL 2017-06-19 48180 ORIG 2017-05-01 47730 ORIG 2017-03-28 47630 ORIG 2017-03-22